Typewriter Therapeutics builds mRNA‑based gene therapies using a proprietary transposon platform that enables precise, non‑viral insertion of therapeutic genes into patient cells. By delivering mRNA encoding a transient transposase and modular therapeutic cassette, the system reduces integration‑related toxicity while supporting rapid development of treatments for monogenic disorders. The company offers a scalable, GMP‑compatible manufacturing process and licenses its technology to pharma and biotech partners.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with severe genetic disorders often lack effective treatments because existing gene therapy approaches can be inefficient, imprecise, or limited to viral vectors that pose safety and manufacturing challenges.
Solution
Typewriter Therapeutics develops mRNA‑based gene therapies that use a proprietary transposon platform to achieve precise, targeted insertion of therapeutic genes into patient cells. By delivering mRNA encoding the transposase and the therapeutic cassette, the system enables transient expression of the editing machinery, reducing the risk of integration‑related toxicity while ensuring durable gene correction. The platform is designed to be adaptable across a range of monogenic diseases, allowing rapid development of bespoke therapies. Manufacturing leverages scalable mRNA production processes, facilitating global distribution and compliance with regulatory standards. The company operates research facilities in Tokyo and Cambridge to accelerate preclinical validation and clinical translation of its pipeline candidates.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to license or co‑develop precise, non‑viral gene therapy solutions for monogenic disorders, as well as clinical research organizations conducting early‑stage trials.
Features
- mRNA‑encoded transposase system for non‑viral, site‑specific gene insertion
- Transient expression of editing components to minimize off‑target effects and immune responses
- Modular therapeutic cassette design enabling rapid re‑targeting to different disease genes
- Scalable, GMP‑compatible mRNA manufacturing workflow
- Dual‑site R&D infrastructure (Japan and USA) supporting accelerated preclinical and clinical development